COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,610 Articles (22,913 medRxiv, 8,697 bioRxiv)

Most recent first Previous |  Page 2348: Articles 23471-23480  | Next

The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans.
Pancer, K., Milewska, A., Owczarek, K., Dabrowska, A., Branicki, W., Sanak, M., Pyrc, K.
10.1101/2020.08.29.257360 — Posted: 2020-08-29
A simplified cell-based assay to identify coronavirus 3CL protease inhibitors
Resnick, S. J., Iketani, S., Hong, S. J., Zask, A., Liu, H., Kim, S., Melore, S., Nair, M. S., Huang, Y., Tay, N. E. S., Rovis, T., Yang, H. W., Stockwell, B. R., Ho, D. D., Chavez, A.
10.1101/2020.08.29.272864 — Posted: 2020-08-29
Universal properties of the dynamics of the Covid-19 pandemics
Chrusciel, P. T., Szybka, S. J.
10.1101/2020.08.24.20181214 — Posted: 2020-08-29
Real-time, interactive website for US-county level Covid-19 event risk assessment
Chande, A., Lee, S., Harris, M., Hilley, T., Andris, C., Weitz, J. S.
10.1101/2020.08.24.20181271 — Posted: 2020-08-29
Where do Brazilian dental students seek information about COVID-19?
Brito Aragao, M. G., Fernandes Gomes, F. I., Siqueira Silva Coelho, C., Pinho Maia Paixao de Melo, L., Milori Corona, S. A.
10.1101/2020.08.24.20179614 — Posted: 2020-08-29
Prevalence of Venous Thromboembolism in Critically-ill COVID-19 Patients: Systematic Review and Meta-analysis
Mohamed, M. F. H., Al-Shokri, S. D., Shunnar, K. M., Mohamed, S. F., Najim, M. S., Ibrahim, S. I., Elewa, H., Dousa, K. M., Abdalla, L. O., El-Bardissy, A., Elshafei, M. N., Abubeker, I. Y., Danjuma, M., Yassin, M. A.
10.1101/2020.08.24.20175745 — Posted: 2020-08-29
Cellular immune response to SARS-CoV-2 infection in humans: a systematic review
Shrotri, M., van Schalkwyk, M. C. I., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., Maher, J., Shields, A. M., Amirthalingam, G., Peacock, S. J., Ismail, S. A.
10.1101/2020.08.24.20180679 — Posted: 2020-08-29 Discussion: Onsite
Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany
Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Richter, A., Schmandke, A., Schmidt, M. L., Schmidt, T. H., De Vries, F. M., Drosten, C., Breteler, M. M. B.
10.1101/2020.08.24.20181206 — Posted: 2020-08-29 Discussion: Onsite
Resolvin D1 and D2 reduce SARS-Cov-2-induced inflammation in cystic fibrosis macrophages
Recchiuti, A., Patruno, S., Mattoscio, D., Isopi, E., Pomilio, A., Lamolinara, A., Iezzi, M., Pecce, R., Romano, M.
10.1101/2020.08.28.255463 — Posted: 2020-08-28
Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutated receptor binding domain with ACE2 receptor
Dash, P., Turuk, J., Behera, S. K., Palo, S. K., Raghav, S., Ghosh, A., Sabat, J., Rath, S., Subhadra, S., Bhattacharya, D., Kanungo, S., Kshatri, J., Mishra, B. k., Dash, S., Mahapatra, N., Parida, A., Pati, S.
10.1101/2020.08.28.271601 — Posted: 2020-08-28 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).